Roundtable Roundup: Relapsed CLL After 2 Prior Lines
In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).
- CASE SUMMARY
- A 65-year-old man who was diagnosed with CLL in 2019 presented to his oncologist at routine follow-up.
- Medical history: type 2 diabetes controlled with insulin
- Patient received previous treatments with:
- First line: acalabrutinib (Calquence) monotherapy
- Achieved good clinical response over 3 years but later progressed on therapy
- Second line: venetoclax (Venclexta) plus rituximab (Rituxan)
- Completed 24-month treatment regimen
- Was in treatment-free interval for 6 months
- Due to disease progression, his hemoglobin has dropped over the past 3 months and is currently at 10 g/dL.
- At follow-up, the patient is now aged 70 years and does not report any symptoms yet.
- ECOG performance status: 0
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
Peers Evaluate CAR T Referral and Bridging Process for Early Relapsed Multiple Myeloma
December 26th 2024During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with lenalidomide-refractory multiple myeloma after 1 prior line of therapy.
Read More
Brunner Discusses Dosing Approaches for ESA and Novel Therapies for Low-Risk MDS
December 23rd 2024During a Case-Based Roundtable® event, Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as dose modifications and safety for the novel agents imetelstat and luspatercept.
Read More
